NCT06709092View on ClinicalTrials.gov

Study on the Effect and Mechanism of Lupatadine Fumarate in the Treatment of Allergic Rhinitis

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Allergic Rhinitis
Interventions
DRUG

lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals)

For patients with AR, patients were given lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals) 1 tablet once daily at bedtime for 14 days.

Trial Locations (2)

210000

NOT_YET_RECRUITING

The First Affiliated Hospital with Nanjing Medical University, Nanjing

RECRUITING

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
lead

Cheng Lei

OTHER